StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Alnylam Pharmaceuticals (ALNY) PT Raised to $250 at Morgan Stanley
June 24, 2024 12:28 PM
Morgan Stanley analyst Andrew Galler raised the price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Analyst PT Change
Next Articles
TD Cowen Reiterates Buy Rating on BridgeBio Pharma (BBIO)
June 24, 2024 11:41 AM
RBC Capital Positive on Alnylam Pharmaceuticals (ALNY): 'HELIOS-B Hits Convincingly Across the Board, Materially Exceeding Expectations'
June 24, 2024 11:38 AM
Alnylam Pharma (ALNY) out of the money July puts and January 260 calls active as share price up 38%
June 24, 2024 11:20 AM
Alnylam (ALNY) data is positive for Ionis (IONS), Intellia (NTLA) and negative for BridgeBio (BBIO) - analyst
June 24, 2024 7:58 AM
BMO Capital Reiterates Outperform Rating on Alnylam (ALNY), Sees Significant Upside Following Data
June 24, 2024 7:52 AM
Midday movers: Apple, Eli Lilly rise; Coinbase falls
June 24, 2024 7:41 AM
Stifel Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY)
June 24, 2024 7:28 AM
Alnylam Pharma (ALNY) to Resume Trading at 7:30 a.m.
June 24, 2024 7:11 AM
BridgeBio Pharma (BBIO) Trades Lower After Alnylam Pharma (ALNY) Reports Positive Data
June 24, 2024 7:10 AM
Alnylam Pharma (ALNY) Reports Positive Topline Results from HELIOS-B Phase 3 Study of Vutrisiran
June 24, 2024 7:00 AM
Alnylam Reports Positive Topline Results from HELIOS-B Phase 3 Study of Vutrisiran, Achieving Statistical Significance on Primary and All Secondary Endpoints in Both Overall and Monotherapy Population
June 24, 2024 7:00 AM
